Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 6/20 | 0.32 |
| ▸ | CA1 | P00915 | 5/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23850653 | 0.83 | ACHE (0.36) | ACHEKMT2AALDH1A1ROCK1 | |
| SCHEMBL22497216 | 0.80 | ACHE (0.38) | ACHEKMT2AALDH1A1CA2CA1 | |
| SCHEMBL22497218 | 0.80 | ACHE (0.38) | ACHEKMT2AALDH1A1CA2CA1 | |
| SCHEMBL17795668 | 0.77 | KMT2A (0.58) | KMT2AALDH1A1CA2CA1CA12 | |
| SCHEMBL23851025 | 0.76 | NAMPT (0.38) | KMT2APTGS2PTGS1CA2CA1 | |
| SCHEMBL30376243 | 0.74 | L3MBTL1 (0.49) | KMT2AALDH1A1CA2PIK3CA | |
| SCHEMBL22021175 | 0.73 | KIT (0.39) | ACHEPTGS2PTGS1CA2CA1 | |
| SCHEMBL25629104 | 0.72 | CA1 (0.39) | KMT2ACA2CA1CA12CA9 | |
| SCHEMBL1662503 | 0.72 | MAPT (0.51) | ACHEKMT2AALDH1A1PIK3CAROCK1 | |
| SCHEMBL21626235 | 0.71 | CA1 (0.41) | KMT2ACA2CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| EP-3883646-A1 | NLRP3 INHIBITORS | Inflazome Limited (IE) | 2021-09-29 | — | — | EP | disclosed |
| CN-113164763-A | NLRP3 inhibitor | 英夫拉索姆有限公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106289-A1 | NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | ACHE 4448/4885KMT2A 4655/4885PTGS2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.